CBA-1535
Model: Antibody Drug Candidate
Category: Pharmaceutical
Exhibitor: CHIOME BIOSCIENCE INC.
Booth No: N1107
Characteristic
"CBA-1535" :Phase I
・Trispecific antibody targeting 5T4 tumor antigen and CD3
・Dose-escalating study is ongoing for solid tumors.
・Discovered utilizing multi-specific antibody platform technology (Tribody®)
・CBA-1535 is a T-cell engager that induces the proliferation and activation of cytotoxic T cells in the presence of 5T4 antigen.
・The substance patent is registered in Japan, the US, EU, UK, China and other countries.
Other Products
Products you may be interested in
Highest Rated Products